OBJECTIVE: Glucose homeostasis is achieved by triggering regulation of glycogen synthesis genes in response to insulin when mammals feed, but the underlying molecular mechanism remains largely unknown. The aim of our study was to examine the role of the signal transducers and activators of transcription 3 (STAT3) in insulin signaling. RESEARCH DESIGN AND METHODS: We generated a strain of mice carrying a targeted disruption of Stat3 gene in the liver (L-Stat3(-/-) mice). Hepatocytes of the L-Stat3(-/-) mice were isolated to establish cell lines for mechanistic studies. Nuclear translocation and DNA-protein interaction of STAT3 was analyzed with immunofluorescent and chromatin immunoprecipitation methods, respectively. Levels of glucose, insulin, leptin, and glucagon were profiled, and putative downstream molecules of STAT3 were examined in the presence of various stimuli in L-Stat3(-/-) and control mice. RESULTS: STAT3 was found to sensitize the insulin signaling through suppression of GSK-3beta, a negative regulator of insulin signaling pathway. During feeding, both mRNA and protein levels of GSK-3beta decreased in Stat3(f/+) mice, which reflected the need of hepatocytes for insulin to induce glycogen synthesis. In contrast, the L-Stat3(-/-) mice lost this control and showed a monophasic increase in the GSK-3beta level in response to insulin. Administration of GSK-3beta inhibitors lithium chloride and L803-mts restored glucose homeostasis and rescued the glucose intolerance and impaired insulin response in L-Stat3(-/-) mice. CONCLUSIONS: These data indicate that STAT3 sensitizes insulin signaling by negatively regulating GSK-3beta. Inactivation of STAT3 in the liver contributes significantly to the pathogenesis of insulin resistance.
OBJECTIVE:Glucose homeostasis is achieved by triggering regulation of glycogen synthesis genes in response to insulin when mammals feed, but the underlying molecular mechanism remains largely unknown. The aim of our study was to examine the role of the signal transducers and activators of transcription 3 (STAT3) in insulin signaling. RESEARCH DESIGN AND METHODS: We generated a strain of mice carrying a targeted disruption of Stat3 gene in the liver (L-Stat3(-/-) mice). Hepatocytes of the L-Stat3(-/-) mice were isolated to establish cell lines for mechanistic studies. Nuclear translocation and DNA-protein interaction of STAT3 was analyzed with immunofluorescent and chromatin immunoprecipitation methods, respectively. Levels of glucose, insulin, leptin, and glucagon were profiled, and putative downstream molecules of STAT3 were examined in the presence of various stimuli in L-Stat3(-/-) and control mice. RESULTS:STAT3 was found to sensitize the insulin signaling through suppression of GSK-3beta, a negative regulator of insulin signaling pathway. During feeding, both mRNA and protein levels of GSK-3beta decreased in Stat3(f/+) mice, which reflected the need of hepatocytes for insulin to induce glycogen synthesis. In contrast, the L-Stat3(-/-) mice lost this control and showed a monophasic increase in the GSK-3beta level in response to insulin. Administration of GSK-3beta inhibitors lithium chloride and L803-mts restored glucose homeostasis and rescued the glucose intolerance and impaired insulin response in L-Stat3(-/-) mice. CONCLUSIONS: These data indicate that STAT3 sensitizes insulin signaling by negatively regulating GSK-3beta. Inactivation of STAT3 in the liver contributes significantly to the pathogenesis of insulin resistance.
Authors: Jianqiang Wu; Vincent W Keng; Deanna M Patmore; Jed J Kendall; Ami V Patel; Edwin Jousma; Walter J Jessen; Kwangmin Choi; Barbara R Tschida; Kevin A T Silverstein; Danhua Fan; Eric B Schwartz; James R Fuchs; Yuanshu Zou; Mi-Ok Kim; Eva Dombi; David E Levy; Gang Huang; Jose A Cancelas; Anat O Stemmer-Rachamimov; Robert J Spinner; David A Largaespada; Nancy Ratner Journal: Cell Rep Date: 2016-02-18 Impact factor: 9.423
Authors: Christopher J Ramnanan; Viswanathan Saraswathi; Marta S Smith; E Patrick Donahue; Ben Farmer; Tiffany D Farmer; Doss Neal; Philip E Williams; Margaret Lautz; Andrea Mari; Alan D Cherrington; Dale S Edgerton Journal: J Clin Invest Date: 2011-08-25 Impact factor: 14.808
Authors: Maximilian Hatting; Clint D J Tavares; Kfir Sharabi; Amy K Rines; Pere Puigserver Journal: Ann N Y Acad Sci Date: 2017-09-03 Impact factor: 5.691
Authors: Eléonore Beurel; Oksana Kaidanovich-Beilin; Wen-I Yeh; Ling Song; Valle Palomo; Suzanne M Michalek; James R Woodgett; Laurie E Harrington; Hagit Eldar-Finkelman; Ana Martinez; Richard S Jope Journal: J Immunol Date: 2013-04-19 Impact factor: 5.422
Authors: Sara Abbadi; Julio J Rodarte; Ameer Abutaleb; Emily Lavell; Chris L Smith; William Ruff; Jennifer Schiller; Alessandro Olivi; Andre Levchenko; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa Journal: Mol Cancer Res Date: 2014-07-07 Impact factor: 5.852
Authors: Derek M Erion; Shin Yonemitsu; Yongzhan Nie; Yoshio Nagai; Matthew P Gillum; Jennifer J Hsiao; Takanori Iwasaki; Romana Stark; Dirk Weismann; Xing Xian Yu; Susan F Murray; Sanjay Bhanot; Brett P Monia; Tamas L Horvath; Qian Gao; Varman T Samuel; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2009-06-22 Impact factor: 11.205
Authors: Florian W Kiefer; Maximilian Zeyda; Karina Gollinger; Birgit Pfau; Angelika Neuhofer; Thomas Weichhart; Marcus D Säemann; René Geyeregger; Michaela Schlederer; Lukas Kenner; Thomas M Stulnig Journal: Diabetes Date: 2010-01-27 Impact factor: 9.461